Replies to post #115897 on Biotech Values

[DewDiligence]

AMLN—Weekly administration may not be much of an advantage…or any advantage at all; please see the interview in #msg-60562015. Moreover, there’s the horse needle to contend with. All told, I think the commercial prospects for Bydureon are bleak. Regards, Dew

p.s. Welcome back. You should post more often :- )